ImmunoIVD is a Swedish company founded in 2015 by researchers who wanted to develop a sensitive SCID assay, suitable for usage in routine newborn screening laboratories. SCID screening gained momentum in Europe around 2015. Initially two pilot studies, one in the Netherlands and one in Sweden were conducted – with both countries deciding to choose the SPOT-it™ kits for the roll-out of national screening. From then on, the number of countries screening for SCID has increased and ImmunoIVD is the proud provider to several laboratories in several European countries.
We are proud of our status as a specialized, research-intensive company keeping the focus on developing rapid and effective assays for newborn screening to facilitate early detection, prompt treatment and more successful outcomes for children affected by primary immunodeficiencies and other rare diseases.